Identify the most promising candidates quickly, whether you’re developing targeted therapies, biologics, or complex modalities like ADCs. By combining speed with PDX-derived fidelity, our platform delivers efficacy data you can trust to guide go/no-go decisions with confidence.
Generate robust IC₅₀ and dose–response curves in days, not week
Scaffold-free format ensures uniform drug penetration and clear imaging for accurate interpretation
Low-passage models maintain native surface marker expression, critical for ADC and biologic evaluation
Ideal for both indication-specific and target-driven screening campaign
Understand not just if a therapy works, but how and why. Champions’ PDXOs preserve tumor architecture and heterogeneity, enabling deeper biological insights that can reveal mechanisms of action, resistance pathways, and biomarkers with real-world relevance.
Supports advanced analytics including RNA-seq, WES, cytokine profiling, flow cytometry, and drug-seq
Identifies molecular drivers of sensitivity and resistance for more precise patient selection
Facilitates evaluation of drug combinations and synergy across therapeutic classes
Bridge preclinical discoveries to in vivo and clinical programs with higher confidence. Our PDXOs replicate patient tumor complexity, making them an ideal tool for hypothesis generation, indication expansion, and precision oncology strategies.
Closely mimic real-world tumor biology for higher predictive accuracy
Inform clinical trial design by aligning ex vivo, in vivo, and patient data
Support multi-omics integration and patient stratification for targeted development
Model immune–tumor interactions in a preserved, clinically relevant microenvironment. Champions’ platform enables nuanced evaluation of immunotherapies with the fidelity needed to predict real-world responses.
Compatible with autologous and allogeneic immune cells, as well as engineered cell therapies
Flow cytometry and imaging provide detailed, dual-compartment readout
Scaffold-free culture enhances immune cell infiltration and functional relevance
Confidently evaluate radionuclide therapies in a model that sustains viability and tumor fidelity over extended timeframes. Champions’ PDXOs enable more accurate pharmacodynamic and retention analyses than conventional systems.
Long-term viability supports extended assay timelines for radionuclide retention and efficacy
Clear, artifact-free imaging for precise interpretation of distribution and effect
Maintains tumor heterogeneity for realistic pharmacodynamic modeling
Discover novel therapeutic opportunities in models that reflect the true complexity of patient tumors. Champions’ PDXOs integrate seamlessly with functional genomics and drug-seq platforms for high-value target identification.
Compatible with CRISPR, RNAi, and drug-seq technologies for functional screening
Identifies new therapeutic dependencies and biomarkers in clinically relevant contexts
Applicable across diverse cancer types, including treatment-resistant and rare models
Test therapeutics in the largest bank of highly characterized primary, never-passaged hematological models from leukemia, lymphoma, & myeloma patients
Evaluate therapeutic efficacy in Champions' matrix-free, multiclonal 3D ex-vivo culture established from unique PDX models
Assess the effect therapeutic agents have on cancer cells and the immune system in the tumor microenvironment
